Abstract: In a coating evaluation device and a coating evaluation method, information on a coating is acquired. The information on a coating includes material information representing a material of a coating surface, and at least one of shape information representing a curved shape of the coating surface, and surface roughness information representing a surface roughness of the coating surface. An evaluation value that corresponds to a combination of the material information, the shape information, and the surface roughness information is estimated by using an evaluation model that outputs a brilliance evaluation value pertaining to the coating surface in response to an input including the material information, the shape information, and the surface roughness information.

Abstract: In a coating evaluation device and a coating evaluation method, a coating surface is irradiated with incident light having a first intensity distribution, and a second intensity distribution of light reflected from the coating surface is acquired. Additionally, a third intensity distribution associated with the second intensity distribution is calculated based on shape information representing a curved shape of the coating surface, and an evaluation value that corresponds to the third intensity distribution is estimated by using an evaluation model that outputs a brilliance evaluation value pertaining to the coating surface in response to an input including the third intensity distribution. The curved shape of the coating surface is acquired based on measuring a coating surface or based on design data pertaining to the coating surface.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X represents —N? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: The present invention relates to a novel azole derivative as an apelin receptor agonist and a method for treating cardiovascular disease, diabetic disease, renal disease, hypertension, and arteriosclerosis, etc., using the same. The present invention provides a compound represented by formula (I) or a pharmacologically acceptable salt thereof wherein X1 represents —NH? or —CH?, X2 represents —CH? or —N?, R1 and R2 each represent a C1 to C6 alkoxy group or the like, R3 represents a heteroaryl group (the heteroaryl group is optionally substituted by a methyl group or the like) or the like, and R4 represents a C1 to C6 alkylthio group or a C2 to C6 alkenyl group (the C1 to C6 alkylthio group and the C2 to C6 alkenyl group are each optionally substituted by one carboxy group or the like) or the like.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the joint structure, respective end portions of a fiber reinforced plastic and a metallic material are joined to each other. A large number of projections having a height that enables the projections to contact fibers constituting the fiber reinforced plastic are formed on a joint surface of the metallic material serving as a part of a joint surface between the fiber reinforced plastic and the metallic material.

Abstract: The present invention provides a modified atrial natriuretic peptide that exhibits prolonged duration in blood and maintains cGMP elevating activity. The present invention provides a modified peptide in which at least one sugar substance is linked directly through a glycosidic bond or via a linker structure to at least one hANP peptide, or a pharmaceutically acceptable salt thereof, a medicament comprising the modified peptide or the salt thereof as an active ingredient, etc.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the structure, multiple single elements are laminated such that the step-shaped structures are superposed in a thickness direction. Each element is constituted by a metallic material including a step-shaped structure having an end portion that gradually becomes thinner towards an end surface thereof so as to form a step-shaped joint surface, and a fiber reinforced plastic laminated such that an end portion thereof covers the step-shaped structure smoothly. A main welding portion is formed on an outer end of the metallic material by welding mating surfaces of adjacent metallic materials. A secondary welding portion is formed on the plastic side of the main welding portion on all the metallic materials by welding them in the thickness direction.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the joint structure, respective end portions of a fiber reinforced plastic and a metallic material are joined to each other. A large number of projections having a height that enables the projections to contact fibers constituting the fiber reinforced plastic are formed on a joint surface of the metallic material serving as a part of a joint surface between the fiber reinforced plastic and the metallic material.

Abstract: There is provided a joint structure for a fiber reinforced resin and a metal. In the structure, multiple single elements are laminated such that the step-shaped structures are superposed in a thickness direction. Each element is constituted by a metallic material including a step-shaped structure having an end portion that gradually becomes thinner towards an end surface thereof so as to form a step-shaped joint surface, and a fiber reinforced plastic laminated such that an end portion thereof covers the step-shaped structure smoothly. The metallic material and the plastic are adhered, and adjacent elements are joined by superposed surfaces thereof. A main welding portion is formed on an outer end of the metallic material by welding mating surfaces of adjacent metallic materials. A secondary welding portion is formed on the plastic side of the main welding portion on all the metallic materials by welding them in the thickness direction.

Abstract: The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, —(CH2)a—X1—(CH2)b—(X1: the formula —NH—, —O— or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].

Abstract: The present invention provides an excellent antihypertensive medicament. The medicament of the present invention comprises a compound having the general formula (I) and the like: [wherein R1: H, substitutable alkyl, substitutable alkenyl, substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; R2: H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R3, R4; H, substitutable alkyl, substitutable alkenyl, substitutable cycloalkyl or the like; R5, R6: H, substitutable alkyl, substitutable cycloalkyl, substitutable alkoxy or the like; R7, R8: H, substitutable alkyl, substitutable cycloalkyl or the like; X: the formula (II) or the like; A: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like; Y: a single bond, substitutable alkylene, substitutable alkenylene, —(CH2)a—X1—(CH2)b—(X1: the formula —NH—, —O— or the like; a, b: 0-5) or the like; B: substitutable cyclic hydrocarbon, substitutable heterocyclyl or the like].

Abstract: The present invention provides a decolorized red phosphorus composition capable of inhibiting coloring in dark red peculiar to red phosphorus even when kneaded with a resin or the like, modified red phosphorus used for the decolorized red phosphorus composition and a production method therefor, and a flame-retardant polymer composition using the decolorized red phosphorus composition. The modified red phosphorus includes red phosphorus particles (A) whose surfaces are coated with a modified resin film (F) containing white particles (B) having a whiteness of 70 or more, color particles (C) having a hue H of 30 to 80 in the Munsell color-system hue circle, and a binder resin (D). The decolorized red phosphorus composition includes a mixed powder containing the modified red phosphorus and white particles (B) having a whiteness of 70 or more. The flame-retardant polymer composition contains the decolorized red phosphorus composition and a polymer compound (I).

Abstract: The present invention provides a decolorized red phosphorus composition capable of inhibiting coloring in dark red peculiar to red phosphorus even when kneaded with a resin or the like, modified red phosphorus used for the decolorized red phosphorus composition and a production method therefor, and a flame-retardant polymer composition using the decolorized red phosphorus composition. The modified red phosphorus includes red phosphorus particles (A) whose surfaces are coated with a modified resin film (F) containing white particles (B) having a whiteness of 70 or more, color particles (C) having a hue H of 30 to 80 in the Munsell color-system hue circle, and a binder resin (D). The decolorized red phosphorus composition includes a mixed powder containing the modified red phosphorus and white particles (B) having a whiteness of 70 or more. The flame-retardant polymer composition contains the decolorized red phosphorus composition and a polymer compound (I).

Abstract: An aqueous zinc nitrite solution contains as impurities 10 ppm or less of sodium (Na) and 100 ppm or less of sulfate ions (SO4) when the aqueous solution has a concentration of zinc nitrite [Zn(NO2)2] of 10% by weight in terms of NO2. Also, disclosed is a method for preparing an aqueous zinc nitrite solution, including a first step of reacting zinc sulfate with calcium nitrite to form an aqueous zinc nitrite solution and a second step of purifying the aqueous zinc nitrite solution.